Sildenafil (Viagra® ) blocks inflammatory injury in LPS-induced mouse abortion: A potential prophylactic treatment against acute pregnancy loss?

Abstract Introduction Recurrent pregnancy losses (RPL) are common women's health issues. Inflammatory and thrombotic events have been associated with RPL including excessive production of cytokines, in particular TNF-α. However, mechanisms behind gestational losses are not yet fully understood....

Full description

Saved in:

Bibliographic Details
Published in:	Placenta (Eastbourne) Vol. 36; no. 10; pp. 1122 - 1129
Main Authors:	Luna, R.L, Nunes, A.K.S, Oliveira, A.G.V, Araujo, S.M.R, Lemos, A.J.J.M, Rocha, S.W.S, Croy, B.A, Peixoto, C.A
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-10-2015
Subjects:	Abortion, Habitual - drug therapy Abortion, Spontaneous - pathology Abortion, Spontaneous - prevention & control Animals Disease Models, Animal Drug Evaluation, Preclinical Female Heparin Internal Medicine Lipopolysaccharides Male Mice Miscarriage Obstetrics and Gynecology Phosphodiesterase 5 Inhibitors - pharmacology Phosphodiesterase 5 Inhibitors - therapeutic use Phosphodiesterase-5 inhibitor Placenta Placenta - drug effects Placenta - ultrastructure Pregnancy Sildenafil Citrate - pharmacology Sildenafil Citrate - therapeutic use Ultrastructure Placenta Heparin Miscarriage Ultrastructure Phosphodiesterase-5 inhibitor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Introduction Recurrent pregnancy losses (RPL) are common women's health issues. Inflammatory and thrombotic events have been associated with RPL including excessive production of cytokines, in particular TNF-α. However, mechanisms behind gestational losses are not yet fully understood. Sildenafil inhibits phosphodiesterase Type-5 (PDE5). This drug increases intracellular cyclic guanosine monophosphate, having vasodilatory and, more recently described, anti-inflammatory properties. PDE5 is present in murine and human uterus and placenta. Sildenafil is already used clinically for treatment of human fetal growth restriction (FGR). Our objective was to determine if Sildenafil alone or in combination with Heparin had protective effects in pregnant Swiss albino challenged to abort by lipopolysaccharide (LPS). Methods Treatments (Sildenafil (50 mg/kg/day), Heparin (500 IU/Kg/day) or Sildenafil + Heparin at the same doses) were initiated the morning of copulation plug detection (gestational day (gd0)). On the 15th day of pregnancy, an intra-peritoneal injection of LPS (100 μg/kg) was administered. Untreated, pregnant mice challenged by LPS served as controls. Results Assessments at 48 h after LPS revealed that Sildenafil + Heparin prevented fetal loss. Early assessments at 2 h after LPS indicated that the pretreatments prevented induction of inflammatory cytokine production (TNF-α, IL-1β/NF-κβ) and preserved placental histopathology. Discussion Combined Sildenafil + Heparin therapy was superior to either treatment alone in most analyses. The known safety of Sildenafil and Heparin in human pregnancy suggests that usage of these combined agents may be of value for treatment of patients with impending pregnancy loss or prophylactically in women with a history of recurrent miscarriages.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0143-4004 1532-3102
DOI:	10.1016/j.placenta.2015.07.133